Overview

Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

This is a pilot, single-center, single-arm study where 20 patients with metastatic or unresectable clear cell renal cell carcinoma will receive same sequential treatment strategy (Cabozantinib for 12 weeks, then proceed with Ipilimumab plus Nivolumab immunotherapy x4 over 12 weeks, then subsequent therapies depending on treatment response for another 12 weeks [Nivolumab for CR/PR/SD, Cabozantinib or Lenvatinib/Everolimus for PROG]).

Phase:

Early Phase 1

Details

Lead Sponsor:

Icahn School of Medicine at Mount Sinai

Treatments:

Everolimus
Ipilimumab
Lenvatinib
Nivolumab